The Pharmacovigilance Analysis of Adverse Events of Erlotinib Based on the Open Access FAERS Database
February 2026
in “
MedBA Medicine
”
Studysummary This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on medbam.org →